Boston Scientific Corp
BSXQ1 2025(BSX Q4 FY2024)Estimated2% AI
AI Revenue %
2%
AI Fair Value
$1.1B
AI Revenue (Q)
$210.3M
Total Revenue (Q)
$10.5B
Source: SEC EDGAR 10-K Filing
View 10-K on SEC.govAnalysis
BSX reported $16,747M in full year 2024 net sales. Q4 standalone = $16,747M - $12,186M = $4,561M. The 10-K describes products including FARAPULSE PFA, SpyGlass digital catheters, EXALT duodenoscopes, Vercise DBS with StimView XT (Brainlab), LATITUDE patient management, and newly acquired Axonics (sacral neuromodulation, closed Q4 2024). Full year Electrophysiology sub-business likely exceeded $1.8B (based on $1,255M through 9 months). The AI/software algorithmic component of these rapidly growing digital medical devices continues to increase. Conservative estimate for Q4: ~$91M. $91M / $4,561M = ~2.0%.
Analyzed by claude-opus-4-6
Quoted Figures
Total net sales $16,747 [million] for year ended December 31, 2024
10-K, FY2024, Consolidated Statements of Operations
MedSurg segment net sales $5,973 [million]; Cardiovascular segment net sales $10,711 [million]
10-K, FY2024, Segment Reporting Note
In the fourth quarter of 2024, we completed the acquisition of Axonics, Inc.
10-K, FY2024, Item 1 Business
AI Products Identified (Ring 1)
FARAPULSE PFA System (pulsed field ablation with mapping)SpyGlass DS II (digital visualization)EXALT Model D (digital duodenoscope)Vercise DBS with StimView XTLATITUDE Patient Management SystemAxonics sacral neuromodulation
AI-Enabled Items (Ring 2 — Not Counted)
These items use AI but are not counted in the AI revenue estimate because they primarily serve non-AI functions.
Electrophysiology productsNeuromodulation hardwareEndoscopy hardwareCardiac Rhythm Management devices
Confidence Tier
EstimatedNo direct AI revenue disclosure — estimated from product mix